<description>&lt;p&gt;Tired of clinic trips and waitlists? Hear how one medtech startup gives mothers real‑time reassurance and lets doctors intervene earlier when it matters most.&lt;/p&gt;&lt;p&gt;In this episode of FemTech at Work, we speak with Amrish Nair, co‑founder of Biorithm, about building a wearable at‑home cardiotocography solution and the broader mission to reduce preventable poor outcomes in pregnancy. Amrish shares the personal and technical origins of the company, why remote fetal monitoring matters, how Biorithm integrates maternal vitals (blood pressure, glucose) with fetal signals, and the clinical evidence from trials across Singapore, Australia, UK and the US. He also explains why Biorithm positions itself as medtech rather than FemTech, how they earned clinical trust through transparent data and key opinion leaders, and why AI must be grounded in high‑quality maternal datasets to be truly useful. &lt;/p&gt;&lt;p&gt;This conversation also dives into fundraising lessons, regulatory strategy, and a long‑term vision that treats pregnancy as a window into a woman’s decades‑long health trajectory.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Key Takeaways:&lt;/strong&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Find out how a hospital cardiotocogram (CTG) was redesigned into a wearable patch&lt;/li&gt;&lt;li&gt;Learn why combining fetal monitoring with home blood pressure and glucose data may detect pre‑eclampsia and gestational diabetes earlier, and how this might reduce stillbirth risk&lt;/li&gt;&lt;li&gt;Discover why Biorithm chose to pitch as medtech and how that positioning changed investor conversations, and what differences regulatory and funding strategies make&lt;/li&gt;&lt;li&gt;Understand how clinical trust is built and what role transparent trials and key opinion leaders play in convincing doctors to adopt remote monitoring&lt;/li&gt;&lt;li&gt;Find out where the industry stands on AI for maternal health and why a better, causal, outcome‑linked data must come first&lt;/li&gt;&lt;li&gt;Discover the founder tradeoffs behind long‑term health startups and why sacrifices and supports matter when you commit eight years to building medtech&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Resources:&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;Amrish Nair: &lt;a target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/amrish-nair-a654314b/"&gt;LinkedIn&lt;/a&gt;&lt;/p&gt;&lt;p&gt;Biorithm: &lt;a target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/biorithm/"&gt;LinkedIn&lt;/a&gt;&lt;/p&gt;&lt;p&gt;Biorithm: &lt;a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bio-rithm.com/"&gt;https://www.bio-rithm.com/&lt;/a&gt;&lt;/p&gt;&lt;p&gt;Maaike Steinebach : &lt;a target="_blank" rel="noopener noreferrer nofollow" href="http://linkedin.com/in/maaike-steinebach-8a3a304"&gt;LinkedIn&lt;/a&gt;&lt;/p&gt;&lt;p&gt;Website Femtech Future &lt;a target="_blank" rel="noopener noreferrer nofollow" href="https://www.femtechfuture.com"&gt;https://www.femtechfuture.com&lt;/a&gt;&lt;/p&gt;&lt;p&gt;Instagram Femtech Future: @femtech_future&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Today’s episode shows how a personal mission became medtech that brings hospital‑grade fetal and maternal monitoring into the home. BioRhythm’s approach reframes prenatal care as prevention, builds clinical trust with transparent data, and paves the way for healthier mothers and babies long after birth.&lt;/p&gt;&lt;p&gt;If this moved you, help turn listening into impact! Subscribe, leave a review, and share this episode with your network. Join the movement to bring better pregnancy care home! Tune in next week for another story that matters.&lt;/p&gt;</description>

Femtech At Work

Maaike Steinebach

Hospital Accuracy, Home Comfort: The Story Behind Biorithm’s Wearable CTG

NOV 13, 202532 MIN
Femtech At Work

Hospital Accuracy, Home Comfort: The Story Behind Biorithm’s Wearable CTG

NOV 13, 202532 MIN

Description

<p>Tired of clinic trips and waitlists? Hear how one medtech startup gives mothers real‑time reassurance and lets doctors intervene earlier when it matters most.</p><p>In this episode of FemTech at Work, we speak with Amrish Nair, co‑founder of Biorithm, about building a wearable at‑home cardiotocography solution and the broader mission to reduce preventable poor outcomes in pregnancy. Amrish shares the personal and technical origins of the company, why remote fetal monitoring matters, how Biorithm integrates maternal vitals (blood pressure, glucose) with fetal signals, and the clinical evidence from trials across Singapore, Australia, UK and the US. He also explains why Biorithm positions itself as medtech rather than FemTech, how they earned clinical trust through transparent data and key opinion leaders, and why AI must be grounded in high‑quality maternal datasets to be truly useful. </p><p>This conversation also dives into fundraising lessons, regulatory strategy, and a long‑term vision that treats pregnancy as a window into a woman’s decades‑long health trajectory.</p><p></p><p><strong>Key Takeaways:</strong></p><ul><li>Find out how a hospital cardiotocogram (CTG) was redesigned into a wearable patch</li><li>Learn why combining fetal monitoring with home blood pressure and glucose data may detect pre‑eclampsia and gestational diabetes earlier, and how this might reduce stillbirth risk</li><li>Discover why Biorithm chose to pitch as medtech and how that positioning changed investor conversations, and what differences regulatory and funding strategies make</li><li>Understand how clinical trust is built and what role transparent trials and key opinion leaders play in convincing doctors to adopt remote monitoring</li><li>Find out where the industry stands on AI for maternal health and why a better, causal, outcome‑linked data must come first</li><li>Discover the founder tradeoffs behind long‑term health startups and why sacrifices and supports matter when you commit eight years to building medtech</li></ul><p></p><p><strong>Resources:</strong></p><p>Amrish Nair: <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/amrish-nair-a654314b/">LinkedIn</a></p><p>Biorithm: <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/biorithm/">LinkedIn</a></p><p>Biorithm: <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bio-rithm.com/">https://www.bio-rithm.com/</a></p><p>Maaike Steinebach : <a target="_blank" rel="noopener noreferrer nofollow" href="http://linkedin.com/in/maaike-steinebach-8a3a304">LinkedIn</a></p><p>Website Femtech Future <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.femtechfuture.com">https://www.femtechfuture.com</a></p><p>Instagram Femtech Future: @femtech_future</p><p></p><p>Today’s episode shows how a personal mission became medtech that brings hospital‑grade fetal and maternal monitoring into the home. BioRhythm’s approach reframes prenatal care as prevention, builds clinical trust with transparent data, and paves the way for healthier mothers and babies long after birth.</p><p>If this moved you, help turn listening into impact! Subscribe, leave a review, and share this episode with your network. Join the movement to bring better pregnancy care home! Tune in next week for another story that matters.</p>